CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner

Combining immunotherapy with targeted therapy has increasingly become an appealing therapeutic paradigm for cancer treatment due to its great potential for generating durable and synergistic antitumor response. In this study, however, we unexpectedly found that two types of CpG-based tumor peptide v...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncogene
Egile Nagusiak: Huang, L, Wang, Z, Liu, C, Xu, C, Mbofung, R M, McKenzie, J A, Khong, H, Hwu, P, Peng, W
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2017
Gaiak:
Short Communication
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5509483/
https://ncbi.nlm.nih.gov/pubmed/28263973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2017.35
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak